Biocon, Mylan launch insulin biosimilar Semglee in Australia market

Topics Biocon | Diabetes

Biocon on Thursday said it had launched insulin biosimilar Semglee, co-developed by Mylan, in Australia. 

Biocon Biologics Chief Executive Officer Christiane Hamacher said: “We are confident that availability of Semglee, a high-quality biosimilar insulin Glargine, through the pharmaceutical benefits scheme will expand patient access to this therapy in Australia.” Insulin Glargine is used for the treatment of type 1 diabetes mellitus in adults, adolescents, and children aged six years and above and type 2 diabetes mellitus in adults. It is given once daily to help control the blood sugar levels of those with diabetes.  

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel